Biotech Goes Sky-High After LSD Drug Treats Depression
Definium Therapeutics shares climb following the release of phase 3 clinical trial results for an LSD-based depression treatment.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
Definium Therapeutics has reported findings from its phase 3 Emerge study focusing on the use of an LSD-based formula to treat major depressive disorder. Coverage indicates that the drug performance in these late-stage trials has resulted in an upward movement for the company's stock.
Reports from Yahoo Finance, Fierce Biotech, Business Wire, Reuters, and Investor's Business Daily highlight the positive reception of the data. Coverage details that the results are considered pivotal for the organization.
The company has scheduled a discussion regarding the topline results of the Emerge study for today, June 22, 2026. Further developments depend on the content of these upcoming company communications.
Synthesized by PULSE from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 1h ago.
Quick answers
What is the focus of the new Definium Therapeutics drug?
The drug is an LSD-based formula designed to treat major depressive disorder.
What stage of clinical trials did the drug complete?
The drug completed phase 3 of the Emerge study.
When are the study results being discussed?
Definium Therapeutics is set to discuss the topline results on June 22, 2026.
Coverage (5)
- DFTX Stock Rallies Ahead Of High-Stakes Phase 3 Depression Drug Trial Results Yahoo Finance · 3h ago
- Definium’s LSD formula produces ‘best data ever seen’ in a pivotal depression trial, CEO says Fierce Biotech · 3h ago
- Definium Therapeutics to Discuss Topline Results from Phase 3 Emerge Study in Major Depressive Disorder on June 22, 2026 Business Wire · 3h ago
- Definium's LSD-based depression pill delivers strong late-stage results, shares surge Reuters · 3h ago
- Biotech Goes Sky-High After LSD Drug Treats Depression Investor's Business Daily · 3h ago
Topics
Related trends
AbbVie to Acquire Apogee Therapeutics, Deepening Immunology Portfolio
AbbVie has announced a $10.9 billion acquisition of Apogee Therapeutics to expand its immunology drug portfolio.
AbbVie nears $11 billion deal for Apogee Therapeutics, FT reports
Pharmaceutical giant AbbVie is reportedly closing in on an $11 billion deal to acquire biotech firm Apogee Therapeutics.
FDA panel considers a first-of-its-kind flu vaccine using mRNA technology
An FDA advisory committee has unanimously backed Moderna's mRNA-based flu vaccine, marking a significant development for the technology.
Biogen Expands Immunology Pipeline with Agreement to Acquire RayThera Inc.
13 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
The Surprising FDA View That Sent Moderna Stock Flying
Moderna stock prices increased following positive feedback from the FDA regarding the company's mRNA influenza vaccine candidate.
Parabilis now the largest VC-backed biotech IPO
Parabilis Medicines’ $745M IPO redefines biotech funding—now the largest VC-backed debut in history.